Dectin-1-activated dendritic cells: A potent Th9 cell inducer for tumor immunotherapy. (1st November 2016)

• Record Type: Journal Article
• Authors: Chen, Jintong; Zhao, Yinghua; Chu, Xiao; Lu, Yong; Wang, Siqing; Yi, Qing
• Is Part Of: Oncoimmunology. Volume 5:Number 11(2016)
• Publication Date: 2016-11-01
• Subjects: Antitumor immunity -- Dectin-1 -- dentritic cells -- Th9 -- Vaccine; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2016.1238558
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: Dendritic cell (DC)-based immunotherapy has great promise for cancer treatment. We have recently demonstrated that dectin-1-activated DCs trigger potent antitumor Th9 cells in vivo . Dectin-1-activated DC-induced antitumor responses rely on the induced Th9/IL-9. These findings offer new strategies for the development of more effective DC vaccines in tumor immunotherapy.